SpaceX's Next Big Business Isn't Rockets. It's Computer Chips.

SpaceX’s $55B initial investment (up to $119B total) for Terafab targets AI-data-center chips for potential space-based deployment, but the plan is early and “not revenue” yet. SpaceX’s 2025 revenue mix remains dominated by Starlink—about 61% ($11.4B) with 10M+ subscribers—so Terafab adds high-capital, years-away optionality rather than near-term cash flow. Given SpaceX’s >$2T valuation already pricing substantial optimism, the article frames Terafab as upside optionality and advises investors to keep positions small.

Analysis

SPCX is being valued on a multi-year optionality story before there is any evidence the economics work. The market risk is not the chip project itself; it is capital allocation creep that can dilute returns from the higher-conviction businesses that actually fund the ecosystem. In the next few weeks the stock can still trade on narrative momentum, but over 1-3 months the more important question is whether investors start haircutting the implied growth rate because the incremental dollars are being pushed into a highly uncertain, long-dated project.

INTC is the cleaner relative beneficiary, but the upside is mostly reputational unless the contribution translates into a measurable foundry backlog or pricing power. If the market reads this as validation of leading-edge process competence, INTC could get a sentiment lift without much near-term earnings impact. The contrarian risk is that the setup becomes another false dawn for the foundry thesis: headline association improves multiple briefly, but the core issue remains yield, customer commitments, and capex intensity.

TSLA is the more interesting second-order name because the ecosystem logic raises the probability of cross-subsidy and management distraction. That can support the AI-optionality narrative, but it also makes TSLA more sensitive to any sign that capital is being diverted away from the auto/robotics cash engine. The consensus is probably underpricing how much of this story depends on external financing and anchored demand; absent that, this is a story-stock premium vulnerable to mean reversion on any update that implies a larger internal capital call.

Key Decisions for Investors

• Short SPCX on any rally into the open; use a 1-3 month put spread rather than outright short if borrow is tight. Thesis: valuation is ahead of verifiable cash flow, and the stock is most exposed to any capex or governance update.
• Pair trade: long INTC / short SPCX over 1-3 months. INTC gets the cleanest sentiment benefit from process-tech validation, while SPCX bears the capital-allocation burden; expected spread works best if the market starts separating optics from earnings.
• Avoid chasing TSLA on this headline. If you already own it, treat the Terafab angle as narrative alpha, not fundamental evidence; trim only if subsequent disclosures show meaningful capital diversion or slower core margin recovery.
• Set an alert for any Terafab financing disclosure or anchor-customer announcement. That is the key falsifier: external funding or committed demand would reduce the short case materially and could force a reassessment within days.